According to the 2022 ELN recommendations, AML is classified into numerous subtypes with respect to genetic abnormalities, including: AML with recurrent genetic abnormalities, AML with mutated TP53, AML with myelodysplasia-related cytogenetic abnormality, and AML not otherwise specified (AML NOS). Here, TP53 is linked to acute myeloid leukemia.